Gide has advised Inventiva, a French company listed on the regulated market of Euronext in Paris, on its initial public offering on the Nasdaq Global Market, by way of a capital increase consisting of a public offering of ordinary shares in the form of American Depositary Shares (ADSs) each representing one ordinary share, for aggregate gross proceeds of USD 107.7 million.
Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, mucopolysaccharidoses, or MPS, and other diseases with significant unmet medical need.
An international team of Gide advised Inventiva on aspects of French law with, in Paris, partner Arnaud Duhamel, working with associates Aude-Laurène Dourdain and Mariléna Gryparis in Paris, and counsel Théophile Strebelle and associate Mélanie Simon in New York.
Cooley LLP advised Inventiva on aspects of US law. Davis Polk advised the banking syndicate on aspects of US and French law.